Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BG1805 in Pediatric Relapsed/Refractory AML
NCT06347458Phase 1Not yet recruiting
- Sponsor
- Guangzhou Bio-gene Technology Co., Ltd.
- Start
- Apr 2024
- Primary completion
- Apr 2027
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of Autologous anti-CLL-1 CAR T lymphocytes BG1805 in acute myeloid leukemia (AML), sponsored by Guangzhou Bio-gene Technology Co., Ltd. Primary endpoints: Dose Limited Toxicity Rate at 28 days and Incidence of Treatment-Emergent Adverse Events at 24 months. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
Autologous anti-CLL-1 CAR T lymphocytes BG1805
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06347458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06347458.